why choose us

First received: June 23, 2023

Clinical Trial: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Malignant Neoplasm

Study Type: INTERVENTIONAL


Official Title: A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA-2

Brief Summary: NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.The goal of this clinical trial is to learn whether NPX267 is safe and tolerable in patients whose cancers are known to express HHLA2 including epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer.The main questions it aims to answer are:what is an appropriate dose to be given to patients?are the side effects of treatment manageable?Participants will be…

Read more